Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-20. (Canceled)

21. (Previously presented) A therapeutic or prophylactic method for treating an immune disorder, comprising:

administering to a patient suffering from or susceptible to the immune disorder a pharmaceutically acceptable dose of rhesus cytomegalovirus (CMV) IL-10.

22. (Previously presented) The method of claim 21, wherein the rhesus CMV IL-10 is a component of a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

23. (Previously presented) The method of claim 22, wherein the pharmaceutical composition is sterile, substantially isotonic and prepared under GMP conditions.

24. (Previously presented) The method of claim 21, wherein the immune disorder is selected from the group consisting of graft-versus-host disease, an autoimmune disease, an inflammatory response, a pathologic delayed type hypersensitivity response, endotoxin-induced toxic shock, granulomatis disease, psoriasis, uveitis, systemic lupus erythematous, multiple sclerosis and contact-dermatitis.

25. (Previously presented) The method of claim 21, further comprising monitoring proliferation of lymphocytes in the patient to detect a reduction in the level of lymphocyte proliferation responsive to the administering step.

26. (Previously presented) The method of claim 21, further comprising monitoring the patient to detect amelioration of a symptom associated with the immune disorder.

27. (Previously presented) The method of claim 21, wherein the patient is suffering from the disorder and the method is a therapeutic treatment method.

28. (Previously presented) The method of claim 21, wherein the patient is susceptible to the disorder and the method is a prophylactic treatment method.

29. (Previously presented) The method of claim 28, wherein the patient is an organ transplant patient.

30. (Previously presented) The method of claim 29, wherein the organ is a kidney.

31. (Previously presented) The method of claim 30, wherein sufficient rhesus CMV IL-10 is administered such that an IFN-ÿ level of the patient is detectably decreased.

32. (Previously presented) The method of claim 21, wherein the immune disorder is a chronic inflammatory disease.

33. (Previously presented) The method of claim 32, wherein the chronic inflammatory disease is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Graves' disease, Hashimoto's thyroiditis, systemic lupus erythematosus, multiple sclerosis, scleroderma, and insulin-dependent diabetes mellitus.

34. (Previously presented) The method of claim 21, wherein the immune disorder is an allergic response.

35. (Previously presented) The method of claim 34, wherein the immune disorder is asthma.

36. (Previously presented) The method of claim 21, wherein the immune disorder is a type TH1 immune response to a transplanted graft.

37. (Previously presented) The method of claim 36, wherein the transplanted graft is an organ selected from the group consisting of cornea, lung, heart, liver, bone marrow, kidney, pancreas, blood, and skin.

38. (Previously presented) The method of claim 25, wherein the immune disorder is leukemia.

39-43. (Canceled)

44. (Previously presented) A therapeutic or prophylactic method for treating an inflammatory response, comprising administering to a patient suffering from or susceptible to the inflammatory response a pharmaceutically acceptable dose of rhesus CMV IL-10.

45. (Previously presented) The method of claim 44, further comprising monitoring proliferation of leukocytes in the patient to detect a reduction in the level of leukocyte proliferation responsive to the administering step.

46. (Currently amended) The method of claim 44, further comprising monitoring the patient to detect amelioration of a symptom associated with the ~~immune disorder~~ inflammatory response.

47. (Previously presented) The method of claim 44, wherein the patient is suffering from the disorder and the method is a therapeutic method.

48. (Previously presented) The method of claim 44, wherein the inflammatory response is a chronic inflammatory disease.

49. (Previously presented) The method of claim 48, wherein the chronic inflammatory disease is selected from the group consisting of rheumatoid arthritis, Crohn's disease, ulcerative colitis, Graves' disease, Hashimoto's thyroiditis and insulin-dependent diabetes mellitus.

50. (Previously presented) The method of claim 21, wherein the patient is a human.

51. (Previously presented) The method of claim 21, wherein the pharmaceutically acceptable dose is administered as a single dose.

52. (Previously presented) The method of claim 21, wherein the pharmaceutically acceptable dose is administered as part of a multi-dose regime.

53. (Previously presented) The method of claim 50, wherein rhesus CMV IL-10 is administered in an amount sufficient to inhibit proliferation of lymphocytes in the human patient.

54. (Previously presented) The method of claim 50, wherein rhesus CMV IL-10 is administered in an amount sufficient to inhibit proliferation of peripheral blood mononuclear cells in the peripheral blood of the human patient.

55. (Previously presented) The method of claim 50, wherein rhesus CMV IL-10 is administered in an amount sufficient to inhibit cytokine production in the human patient.

56. (Previously presented) The method of claim 44, wherein the patient is susceptible to the inflammatory response and the method is a prophylactic treatment method.

57. (Previously presented) The method of claim 44, wherein the patient is a human.

58. (Previously presented) The method of claim 44, wherein the pharmaceutically acceptable dose is administered as a single dose.

59. (Previously presented) The method of claim 44, wherein the pharmaceutically acceptable dose is administered as part of a multi-dose regime.

60. (Previously presented) The method of claim 57, wherein rhesus CMV IL-10 is administered in an amount sufficient to inhibit proliferation of peripheral blood mononuclear cells in the peripheral blood of the human patient.

61. (Previously presented) The method of claim 57, wherein rhesus CMV IL-10 is administered in an amount sufficient to inhibit cytokine production in the human patient.